Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Trial of Avelumab in Combination With Chemoradiation in the Treatment of Stage II/III Resectable Esophageal and Gastroesophageal Cancer

Next Previous
Trial Profile

Phase I/II Trial of Avelumab in Combination With Chemoradiation in the Treatment of Stage II/III Resectable Esophageal and Gastroesophageal Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Large cell carcinoma; Oesophageal cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 07 Jun 2022 Enrollment was stopped after 16 patients in the expansion cohort due to accrual delays and changes in standard treatment
    • 07 Jun 2022 Results assessing safety and efficacy of avelumab with perioperative CRT in resectable esophageal and gastroesophageal junction cancer, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
    • 28 Mar 2022 Planned End Date changed from 1 Feb 2024 to 1 Mar 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top